Piper Sandler raised the firm’s price target on Blueprint Medicines to $78 from $58 and keeps a Neutral rating on the shares. Blueprint Medicines is deprioritizing and discontinuing their lead lung cancer programs, and while the company is guiding to a year over year decline in opex for 2024, the firm is looking for more clarity around FY24 guidance when the company reports Q4/FY23 results in February, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BPMC:
- Blueprint Medicines says AYVAKIT has potential to be multibillion-dollar therapy
- Blueprint Medicines price target raised to $114 from $89 at Goldman Sachs
- Blueprint Medicines price target raised to $97 from $95 at Stifel
- Biotech Alert: Searches spiking for these stocks today
- Blueprint Medicines announces European Commission approval of AYVAKYT
